Written by :
Posted on :

February 21, 2024

Kolosis BIO Announces Strong 2023 Results

  • Kolosis bone grafts continue gaining substantial market presence, now available in over 450 hospitals and surgical facilities across 48 states
  • Kore Fiber and Prime HD grafts utilized in over 16,000 fusion procedures in 2023, a 33% increase from the previous year.
  • Kolosis BIO channel partners now topping more than 200 independent distributors in the spine and orthopedic space
  • Expanded partnership with MTF into the Surgical Wound Market
  • A Utah Fast 50 Emerging Company for FY2023


SALT LAKE CITY, UTAH — Kolosis BIO, LLC (Kolosis), a Salt Lake City based biologics company and exclusive partner to MTF Biologics, proudly announces its 2023 results as it looks towards expected 2024 performance.

Kolosis leadership recognizes the impressive gains made by the company over the past year. “I couldn’t be more excited about our progress over the past year and seeing our tissues become a trusted choice in over 450 hospitals across the country,” said Collin Begley, CEO of Kolosis. “This success speaks volumes about the potential of our disruptive technologies.”

About Kolosis BIO:

Kolosis BIO is a leading provider of innovative biologic solutions, dedicated to commercializing cutting-edge technologies and delivering market-leading products to the orthopedic industry. As a pure-play biologics company, Kolosis BIO exclusively partners with MTF Biologics to offer superior quality bone graft technologies such as Kore Fiber, a 100% cortical fiber allograft and Prime HD, a pre-hydrated DBM. These allografts are backed by MTF’s proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.

As the company looks to the future, Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit

About MTF Biologics:

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe. For more information, visit